The Data Behind the New GLP-1 Contender

For patients managing type 2 diabetes, the standard of care has shifted rapidly toward GLP-1 receptor agonists. Now, a new entrant is challenging the current market leader. A phase 2b multicenter randomized trial published in the Annals of Internal Medicine suggests that bofanglutide, a novel GLP-1 agonist, may provide more significant reductions in hemoglobin A1c (HbA1c) levels than semaglutide.

The study, led by Dr. Ming Liu of Tianjin Medical University General Hospital, tracked 272 adults with type 2 diabetes who were either drug-naive or on stable oral medication. Over 24 weeks, participants received varying doses of bofanglutide—administered either biweekly or once weekly—or a once-weekly 1 mg dose of semaglutide. The results indicate that bofanglutide consistently outperformed the 1 mg semaglutide benchmark in lowering blood glucose markers.

How the Numbers Compare

The primary endpoint of the study was the change in HbA1c from baseline to week 24. The findings were statistically significant across all bofanglutide dosage groups:

  • Bofanglutide 12 mg (Q2W): −1.87 percent
  • Bofanglutide 18 mg (Q2W): −2.28 percent
  • Bofanglutide 24 mg (Q2W): −1.94 percent
  • Bofanglutide 24 mg (QW): −2.32 percent
  • Semaglutide 1 mg (QW): −1.60 percent

When compared directly to the semaglutide group, the treatment differences ranged from −0.27 to −0.72 percent. While these results are promising, the study also highlighted a higher incidence of gastrointestinal side effects in the bofanglutide groups, ranging from 81.8 to 87.3 percent, compared to 51.9 percent for those on semaglutide. Most of these events were classified as mild to moderate in severity.

What Experts Say

The study authors noted that the 24-week treatment period resulted in meaningful glycemic control, weight loss, and improvements in various cardiometabolic risk factors. They emphasized that the reductions observed were at least as large—or larger—than those seen with the 1 mg dose of semaglutide, which is currently the highest approved dose for type 2 diabetes in many clinical settings.

However, the trial was funded by Gan & Lee Pharmaceuticals, and several authors disclosed financial ties to the company. This funding structure is common in phase 2b trials but underscores the need for larger, independent phase 3 trials to confirm these efficacy and safety profiles in more diverse, global patient populations.

Key Takeaways

  • Bofanglutide demonstrated superior HbA1c reduction compared to 1 mg of semaglutide in a 24-week phase 2b trial.
  • Gastrointestinal side effects were more frequent in the bofanglutide groups, though they were primarily mild or moderate.
  • The trial was funded by the drug's manufacturer, Gan & Lee Pharmaceuticals, necessitating further independent verification.

Looking Ahead

While these results offer a compelling case for bofanglutide's efficacy, the path to clinical adoption remains long. The next critical milestone will be the design and execution of phase 3 trials, which must address whether the higher rate of gastrointestinal side effects will impact long-term patient adherence. Clinicians and patients should watch for upcoming data on long-term safety and cardiovascular outcomes, which will likely be the deciding factors for regulatory approval and eventual inclusion in standard treatment guidelines.

This article is for informational purposes only. Always consult a qualified healthcare professional before making any medical decisions.